---
layout: default
title: Flucloxacillin
parent: Model Prediction Only (L5)
nav_order: 354
evidence_level: L5
indication_count: 10
---

# Flucloxacillin
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Flucloxacillin: From Staphylococcal Infections to Conjunctivitis

## One-Sentence Summary

Flucloxacillin is a narrow-spectrum, penicillinase-resistant β-lactam antibiotic traditionally used against susceptible staphylococcal and streptococcal infections. The TxGNN model predicts it may be effective for **Conjunctivitis**, but this is currently supported only by **0 clinical trials** and **2 indirect publications**, none of which studied flucloxacillin for this indication directly.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not formally recorded (data gap); pharmacologically, staphylococcal/streptococcal infections based on drug class |
| Predicted New Indication | Conjunctivitis |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L4 (mechanism-based, no direct clinical evidence) |
| Taiwan Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action (MOA) data for flucloxacillin is not available from DrugBank (flagged as a High-severity data gap). Based on known pharmacological classification, flucloxacillin is a narrow-spectrum, penicillinase-resistant isoxazolyl penicillin with established antibacterial activity against *Staphylococcus aureus* and other Gram-positive organisms.

Bacterial conjunctivitis can be caused by *S. aureus* and related organisms, so there is a plausible general antibacterial-spectrum rationale for flucloxacillin's activity in this setting. However, this is a class-level extrapolation rather than indication-specific pharmacological evidence — nothing in the evidence pack directly links flucloxacillin's mechanism to ocular/conjunctival tissue penetration or efficacy.

Importantly, the two literature items identified both discuss conjunctivitis only as a secondary or prodromal clinical feature of unrelated conditions (staphylococcal scalded skin syndrome; atypical herpes simplex presentations) rather than as a treatment target for flucloxacillin itself. The TxGNN graph-based score is therefore likely capturing a co-occurrence signal (staphylococcal disease ↔ conjunctivitis) rather than direct treatment evidence, which is consistent with the model's own L4/Hold classification for this candidate.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [12627992](https://pubmed.ncbi.nlm.nih.gov/12627992/) | 2003 | Review | American Journal of Clinical Dermatology | Reviews staphylococcal scalded skin syndrome (SSSS); notes conjunctivitis as a prodromal symptom, not a flucloxacillin treatment study |
| [1286123](https://pubmed.ncbi.nlm.nih.gov/1286123/) | 1992 | Review/Case report | International Journal of STD & AIDS | Reviews atypical presentations of herpes simplex virus infection; abstract unavailable, no direct relevance to flucloxacillin established |

## Taiwan Market Information

Flucloxacillin currently has no marketing authorization records in Taiwan (0 registrations, status: Not marketed/Not Marketed).

## Safety Considerations

Please refer to the package insert for safety information. (Note: TFDA label warnings/contraindications and DDI database results were not retrievable at time of this report — see Conclusion below.)

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The conjunctivitis prediction rests on L4 (mechanism/graph-inference) evidence only, with no clinical trials and no literature directly evaluating flucloxacillin for this indication. The drug also has no current market presence in Taiwan and a blocking gap in TFDA safety data, which prevents any safety pre-assessment (S1 stage).

**To proceed, the following is needed:**
- TFDA product label (warnings/contraindications) — blocking gap, required before S1 safety review
- DrugBank mechanism of action detail — required for mechanistic-relevance analysis
- Indication-specific preclinical or clinical data on flucloxacillin in bacterial conjunctivitis
- Complete DDI database query (current query failed due to missing local DDInter data file)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

